EVs

电动汽车
  • 文章类型: Journal Article
    小细胞外囊泡(sEV)的直径通常为30-150nm,在细胞内产生,并释放到细胞外空间。这些囊泡携带RNA,DNA,蛋白质,和反映其亲本细胞特征的脂质,使细胞之间的通信和功能的改变或分化的靶细胞。由于这些属性,sEV最近作为功能分子和药物递送工具的潜在载体而受到关注。然而,它们作为治疗平台的使用面临着局限性,如大规模生产中的挑战,纯度问题,以及缺乏既定的方案和表征方法。为了克服这些,研究人员正在探索各种应用的电动汽车的表征和工程。这篇综述讨论了sEV的起源及其治疗效果的工程,提出需要深入研究的领域。它涵盖了细胞衍生的sEV在其自然状态和工程形式中用于特定目的的用途。此外,该审查详细介绍了sEV的来源及其随后的纯化方法。它还概述了治疗性sEV的潜力和成功临床试验的要求,包括大规模生产和纯化的方法。最后,我们讨论了正在进行的临床试验的进展以及对未来医疗保健的影响,全面概述了sEV应用的最新研究。
    Small Extracellular Vesicles (sEVs) are typically 30-150 nm in diameter, produced inside cells, and released into the extracellular space. These vesicles carry RNA, DNA, proteins, and lipids that reflect the characteristics of their parent cells, enabling communication between cells and the alteration of functions or differentiation of target cells. Owing to these properties, sEVs have recently gained attention as potential carriers for functional molecules and drug delivery tools. However, their use as a therapeutic platform faces limitations, such as challenges in mass production, purity issues, and the absence of established protocols and characterization methods. To overcome these, researchers are exploring the characterization and engineering of sEVs for various applications. This review discusses the origins of sEVs and their engineering for therapeutic effects, proposing areas needing intensive study. It covers the use of cell-derived sEVs in their natural state and in engineered forms for specific purposes. Additionally, the review details the sources of sEVs and their subsequent purification methods. It also outlines the potential of therapeutic sEVs and the requirements for successful clinical trials, including methods for large-scale production and purification. Finally, we discuss the progress of ongoing clinical trials and the implications for future healthcare, offering a comprehensive overview of the latest research in sEV applications.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Journal Article
    越来越多的证据表明,大多数原代沃顿的果冻间充质干细胞(WJ-MSCs)的治疗潜力是由于他们的旁分泌活性,即,它们通过释放生物活性分子和因子来调节其微环境的能力,这些生物活性分子和因子统称为分泌体。这些生物活性分子和因子可以直接释放到周围的微环境中,或者可以嵌入膜结合的细胞外生物活性纳米大小(通常为30-150nm)的信使颗粒或内体起源的囊泡中,具有特定的生物发生途径。称为外泌体或由相对较大的颗粒(100nm-1μm)携带,这些颗粒由质膜向外起泡形成,称为微囊泡(MV);外泌体和MV统称为细胞外囊泡(EV)。在分泌组中发现的生物活性分子和因子有各种类型,包括细胞因子,趋化因子,细胞骨架蛋白,整合素,生长因子,血管生成介质,荷尔蒙,代谢物,和调节核酸分子。不出所料,分泌组有不同的生物学功能,如免疫调节,组织补充,细胞内稳态,除了具有抗炎和抗纤维化作用。本文综述了WJ-MSCs分泌组的研究进展及其临床应用前景。
    Accumulating evidence indicates that most primary Wharton\'s jelly mesenchymal stem cells (WJ-MSCs) therapeutic potential is due to their paracrine activity, i.e., their ability to modulate their microenvironment by releasing bioactive molecules and factors collectively known as secretome. These bioactive molecules and factors can either be released directly into the surrounding microenvironment or can be embedded within the membrane-bound extracellular bioactive nano-sized (usually 30-150 nm) messenger particles or vesicles of endosomal origin with specific route of biogenesis, known as exosomes or carried by relatively larger particles (100 nm-1 μm) formed by outward blebbing of plasma membrane called microvesicles (MVs); exosomes and MVs are collectively known as extracellular vesicles (EVs). The bioactive molecules and factors found in secretome are of various types, including cytokines, chemokines, cytoskeletal proteins, integrins, growth factors, angiogenic mediators, hormones, metabolites, and regulatory nucleic acid molecules. As expected, the secretome performs different biological functions, such as immunomodulation, tissue replenishment, cellular homeostasis, besides possessing anti-inflammatory and anti-fibrotic effects. This review highlights the current advances in research on the WJ-MSCs\' secretome and its prospective clinical applications.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

公众号